DOI 10.1016/j.amjms.2026.07.001
Effects of CTLA4-Ig, rituximab, and rapamycin on rat-to-mouse cardiac xenograft survival.
Аннотация
BACKGROUND
Xenotransplantation addresses the critical shortage of human organs and tissues; however, innate immune responses and acute humoral rejection (AHR) limit xenograft survival, the regimen of combined medication remains to be further explored.
METHODS
This study aimed to determine whether a clinically applicable immunosuppressive regimen consisting of CTLA4-Ig, rituximab, and rapamycin could synergistically prolong xenograft survival. Hearts were harvested from Sprague-Dawley (SD) rats and transplanted into C57BL/6 mice. Recipient animals were randomly divided into three groups: an untreated control group, a CTLA4-Ig monotherapy group, or a combination therapy group receiving the triple immunosuppressive regimen.
RESULTS
In the control group, cardiac xenografts were rejected within 10 days, characterized by cell-mediated rejection and AHR. In contrast, the combination therapy significantly prolonged xenograft survival and suppressed immune rejection in the treated recipients. Notably, infiltration of T cells, B cells, dendritic cells, macrophages, and natural killer (NK) cells was markedly reduced, complement deposition was decreased, and the production of xeno-reactive antibodies and proinflammatory cytokines were lowered. Furthermore, we confirmed that the combination therapy confers enhanced protection against xenograft injury via inhibition of the PI3K/mTOR signaling pathway.
CONCLUSIONS
These findings strongly support the rationale for administering CTLA4-Ig, rituximab, and rapamycin to constrain innate immune responses and alleviate AHR in xenotransplantation.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.